- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04813562
Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)
A Single-center, Randomized, Double Blinded, Placebo Controlled, Phase 2 Clinical Trial of Recombinant COVID-19 Vaccine (CHO Cells), in the Subjects From Healthy Aged 18 Years and Above
Study Overview
Status
Conditions
Intervention / Treatment
- Biological: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56
- Biological: a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56
- Biological: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56
- Biological: a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56
- Biological: a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56
- Biological: a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56
- Biological: a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56
- Biological: a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56
Detailed Description
This is a phase Ⅱ, single-center, randomized, double-blind, placebo-controlled study, to evaluate the immunogenicity and safety of the recombinant COVID-19 vaccine (CHO cells) in the subjects from healthy adults and elderly adults aged 18 years and above (aged 18-60 and 60-85 years) . The phase Ⅱ clinical trials designed 4 research group, including an immunization procedures (0, 28, 56 days), two doses (20μg/0.5ml, 40μg/0.5ml) and two ages group (adults and elder): Each group including 120 participants. Vaccination or placebo group will be randomly assigned to receive in a 5:1 ratio, 480 in total.
Cellular immune blood samples were collected from the top 96 subjects (i.e., the top 24 in each study group, vaccine group: control group =5:1), and Elispot test and cytokine staining (ICS)/flow assay were performed.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Recruiting
- Jiangsu Provincial Center for Diseases Control and Prevention
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy subjects of ≥ 18 years old.
- The subject can understand and voluntarily sign the informed consent.
- Axillary temperature ≤37.0℃.
- General good health as established by medical history and physical examination
Exclusion Criteria:
- Have a history of close contact with a confirmed case of SARS-CoV-2, an asymptomatic infection in the previous 14 days, or a travel history/residential history in a community where a case has been reported.
- Have a history of contact with a person infected with SARS-CoV-2(a person with a positive nucleic acid test) in the previous 14 days.
- Patients with fever or respiratory symptoms who have been to middle or high-risk areas in the past 14 days or have exit history, or come from communities with case reports.
- In the past 14 days, there have been 2 or more cases of fever and/or respiratory symptoms in small areas such as homes, offices, school classes, etc.
- Have a history of SARS.
- Have a history of SARS-CoV-2 infection or history of Coronavirus Vaccination (including Emergency Vaccine and Experimental Vaccine).
- Positive in SARS-CoV-2 IgG or IgM antibody screening.
- Have a history of HIV infection;
- Women who are breastfeeding, pregnant, or planning to become pregnant during 6 months after full-course vaccination (based on the subject's self-report and blood pregnancy test results for women of childbearing age).
- Have a history of asthma, a history of vaccine or vaccine component allergy, have serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioedema.
- Subjects with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.
- Subjects with autoimmune diseases or immunodeficiency/immunosuppression.
- Subjects with severe chronic diseases, severe cardiovascular diseases, hypertension(sbp≥160mmHg and/or dbp≥100mmHg) and diabetes that cannot be controlled by drugs, liver and kidney diseases, malignant tumors, etc.
- Subjects with severe neurological disease (epilepsy, convulsions or convulsions) or mental illness.
- Subjects with thyroid disease or history of thyroidectomy, no spleen, functional asthenia, and any spleen or splenectomy caused by any condition.
- Abnormal blood coagulation function diagnosed by a doctor (such as coagulation factor deficiency, coagulopathy, abnormal platelet) or obvious bruise or coagulation disorder.
- Have received immunosuppressant therapy, cytotoxic therapy, and inhaled corticosteroids in the past 6 months (excluding corticosteroid spray therapy for allergic rhinitis and surface corticosteroid therapy for acute non-complicated dermatitis).
- Received blood products within 3 months before receiving trial vaccine.
- Received other study drugs within 30 days before receiving the trail vaccine.
- Received a live attenuated vaccine within 14 days before receiving the experimental vaccine.
- Received a subunit or inactivated vaccine within 7 days before receiving the experimental vaccine.
- Various acute or chronic diseases occurred in the past 7 days.
- Have a long history of alcohol or drug abuse.
- Had urticaria one year before receiving the experimental vaccine;
- congenital or acquired angioedema/neuroedema;
- According to the judgment of the investigator, the subject has any other factors that are not suitable for participating in the clinical trial, or Or influence the subject to sign the informed consent.
Exclusion criteria of subsequent dose:
- Patients with severe allergic reactions after the previous dose of vaccination;
- Patients with serious adverse reactions causally related to the previous dose of vaccination.
- For those newly discovered or newly discovered after the first vaccination that does not meet the first-dose selection criteria or meets the first-dose exclusion criteria, the investigator will determine whether to continue participating in the study.
- Other exclusion reasons suggested by the researchers.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Middle-dose vaccine (18-59 years)
Three doses of middle-dose experimental vaccine at the schedule of day 0, 28, 56
|
18-59 years,Three doses of middle-dose (20µg/0.5ml)
recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
|
EXPERIMENTAL: High-dose vaccine (18-59 years)
Two doses of High-dose vaccine at the schedule of day 0, 28, 56
|
18-59 years,Three doses of high-dose (40µg/0.5ml)
recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
|
EXPERIMENTAL: Middle-dose vaccine (60-85 years)
Three doses of middle-dose experimental vaccine at the schedule of day 0, 28, 56
|
60-85 years,Three doses of middle-dose (20µg/0.5ml)
recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
|
EXPERIMENTAL: High-dose vaccine (60-85 years)
Two doses of High-dose experimental vaccine at the schedule of day 0, 28, 56
|
60-85 years,Three doses of high-dose (40µg/0.5ml)
recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.
|
PLACEBO_COMPARATOR: Middle-dose placebo (18-59 years)
Three doses of middle-dose placebo at the schedule of day 0, 28, 56
|
18-59 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
|
PLACEBO_COMPARATOR: High-dose placebo (18-59 years)
Two doses of High-dose placebo at the schedule of day 0, 28, 56
|
18-59 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
|
PLACEBO_COMPARATOR: Middle-dose placebo (60-85 years)
Three doses of middle-dose placebo at the schedule of day 0, 28, 56
|
60-85 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
|
PLACEBO_COMPARATOR: High-dose placebo (60-85 years)
Two doses of High-dose placebo at the schedule of day 0, 28, 56
|
60-85 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody (eucivirus neutralization assays)
Time Frame: 30 days after full-course vaccination in each study group
|
30 days after full-course vaccination in each study group
|
The incidence of adverse reaction (AR)
Time Frame: 0 to 7 days after vaccination in each study group
|
0 to 7 days after vaccination in each study group
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The incidence of adverse events (AE)
Time Frame: 0 to 30 days after vaccination in each study group
|
0 to 30 days after vaccination in each study group
|
The incidence of severe adverse events (SAE)
Time Frame: 12 months after prime and boost vaccination
|
12 months after prime and boost vaccination
|
The Geometric mean titer (GMT) of anti-SARS-CoV-2 specific neutralizing antibody (euvirus and pseudovirus neutralization assays)
Time Frame: 14 days, 30 days, 6 months and 12 months after full-course vaccination in each study group
|
14 days, 30 days, 6 months and 12 months after full-course vaccination in each study group
|
The Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibody (euvirus and pseudovirus neutralization assays)
Time Frame: 14 days, 30 days, 6 months and 12 months after full-course vaccination in each study group
|
14 days, 30 days, 6 months and 12 months after full-course vaccination in each study group
|
The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody (eucivirus neutralization assays)
Time Frame: 14 days, 6 months and 12 months after full-course vaccination in each study group
|
14 days, 6 months and 12 months after full-course vaccination in each study group
|
The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody (pseudovirus neutralization assays)
Time Frame: 14 days, 30days, 6 months and 12 months after full-course vaccination in each study group
|
14 days, 30days, 6 months and 12 months after full-course vaccination in each study group
|
The positive conversion rate of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody
Time Frame: 14 days, 30days, 6 months and 12 months after full-course vaccination in each study group
|
14 days, 30days, 6 months and 12 months after full-course vaccination in each study group
|
The GMT of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody
Time Frame: 14 days, 30days, 6 months and 12 months after full-course vaccination in each study group
|
14 days, 30days, 6 months and 12 months after full-course vaccination in each study group
|
The GMI of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody
Time Frame: 14 days, 30days, 6 months and 12 months after full-course vaccination in each study group
|
14 days, 30days, 6 months and 12 months after full-course vaccination in each study group
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The geometric mean titer (GMT) ratio of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody in each study groups
Time Frame: 14 days, 30days, 6 months and 12 months after full-course vaccination in each study group
|
14 days, 30days, 6 months and 12 months after full-course vaccination in each study group
|
Subtypes of IgG antibodies against the S-RBD protein of SARS-CoV-2 after immunization in each study group
Time Frame: 14 days, 30days, 6 months and 12 months after full-course vaccination in each study group
|
14 days, 30days, 6 months and 12 months after full-course vaccination in each study group
|
The proportion of IFN-γ secreted by T cells at Day 14 using ELISpot detection method
Time Frame: Day 14 after full-course vaccination in each study group
|
Day 14 after full-course vaccination in each study group
|
The Intracellular cytokine staining (ICS)/flow cytometry was used to detect the Th1/Th2 immune response after immunization (CD3+/CD4+/CD8+ T cells, and cytokines TNFα/IFNγ/IL2/IL4).
Time Frame: Day 14 after full-course vaccination in each study group
|
Day 14 after full-course vaccination in each study group
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JSVCT097
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... and other collaboratorsRecruitingCOVID-19 | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Acute COVID-19China
Clinical Trials on a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56
-
Jiangsu Province Centers for Disease Control and...Academy of Military Medical Sciences,Academy of Military Sciences,PLA; ZHONGYIANKE... and other collaboratorsRecruiting
-
Jiangsu Province Centers for Disease Control and...West China HospitalCompleted
-
Memorial Sloan Kettering Cancer CenterTufts Medical Center; Lahey ClinicCompleted